Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection

Dorothy J. Wiley, Edward Wiesmeier, Emmanuel Masongsong, Karen H. Gylys, Laura A. Koutsky, Daron Gale Ferris, Eliav Barr, Jian Yu Rao

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To determine the association between tobacco smoking and serologic evidence of human papillomavirus type 16 (HPV16)-specific antibodies among HPV16 DNA-positive women. Design, Setting, and Participants: Baseline health history, physical examination, and laboratory data for 205 HPV16 DNA-positive women with no prior cytologic evidence of squamous intraepithelial lesions who were enrolled subsequently in a randomized clinical trial. Main Outcome Measure: HPV16-L1 antibody (anti-HPV16 antibody) detected from serum using RIA or ELISA. Results: Eighty-seven percent (179 of 205) of women tested positive for HPV16 DNA using cervicovaginal swabs or lavage specimens, and 26 women showed similar results using swab specimens of external genitalia alone. HPV16-infected women who reported increasingly greater levels of daily cigarette smoking were less likely to test positive for anti-HPV16 antibodies than nonsmoking women (P = 0.02). Smokers were twice as likely as nonsmokers to test negative for anti-HPV16 antibodies, even after controlling for the effects of other covariates in the analyses (adjusted odds ratio, 0.5; 95% confidence limits, 0.2-0.9). Although Papanicolaou test findings and smoking characteristics were poorly correlated (r2 = 0.01), women who showed atypical cells of unknown significance or squamous intraepithelial lesion were twice as likely to test anti-HPV16 antibody positive as women who showed normal Papanicolaou tests (adjusted odds ratio, 2.0; 95% confidence limits, 1.1-3.7). Conclusion: These data suggest that smoking may influence the long-term risk for cancer by perturbing early immune responses to the virus and may increase the likelihood of persistent infection. Patient education messages should alert women to this additional risk of smoking. A clinical trial of smoking cessation should be explored as a therapeutic intervention for primary HPV16 infection.

Original languageEnglish (US)
Pages (from-to)915-920
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number5
DOIs
StatePublished - May 1 2006

Fingerprint

Papillomavirus Infections
Human papillomavirus 16
Antibodies
Smoking
Papanicolaou Test
DNA
Odds Ratio
Genitalia
Therapeutic Irrigation
Smoking Cessation
Patient Education
Physical Examination
Anti-Idiotypic Antibodies
Randomized Controlled Trials
Enzyme-Linked Immunosorbent Assay
Outcome Assessment (Health Care)
Clinical Trials
Viruses

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection. / Wiley, Dorothy J.; Wiesmeier, Edward; Masongsong, Emmanuel; Gylys, Karen H.; Koutsky, Laura A.; Ferris, Daron Gale; Barr, Eliav; Rao, Jian Yu.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 5, 01.05.2006, p. 915-920.

Research output: Contribution to journalArticle

Wiley, Dorothy J. ; Wiesmeier, Edward ; Masongsong, Emmanuel ; Gylys, Karen H. ; Koutsky, Laura A. ; Ferris, Daron Gale ; Barr, Eliav ; Rao, Jian Yu. / Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 5. pp. 915-920.
@article{9a8b9c22eccf471ebee8f4ca601798cb,
title = "Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection",
abstract = "Objective: To determine the association between tobacco smoking and serologic evidence of human papillomavirus type 16 (HPV16)-specific antibodies among HPV16 DNA-positive women. Design, Setting, and Participants: Baseline health history, physical examination, and laboratory data for 205 HPV16 DNA-positive women with no prior cytologic evidence of squamous intraepithelial lesions who were enrolled subsequently in a randomized clinical trial. Main Outcome Measure: HPV16-L1 antibody (anti-HPV16 antibody) detected from serum using RIA or ELISA. Results: Eighty-seven percent (179 of 205) of women tested positive for HPV16 DNA using cervicovaginal swabs or lavage specimens, and 26 women showed similar results using swab specimens of external genitalia alone. HPV16-infected women who reported increasingly greater levels of daily cigarette smoking were less likely to test positive for anti-HPV16 antibodies than nonsmoking women (P = 0.02). Smokers were twice as likely as nonsmokers to test negative for anti-HPV16 antibodies, even after controlling for the effects of other covariates in the analyses (adjusted odds ratio, 0.5; 95{\%} confidence limits, 0.2-0.9). Although Papanicolaou test findings and smoking characteristics were poorly correlated (r2 = 0.01), women who showed atypical cells of unknown significance or squamous intraepithelial lesion were twice as likely to test anti-HPV16 antibody positive as women who showed normal Papanicolaou tests (adjusted odds ratio, 2.0; 95{\%} confidence limits, 1.1-3.7). Conclusion: These data suggest that smoking may influence the long-term risk for cancer by perturbing early immune responses to the virus and may increase the likelihood of persistent infection. Patient education messages should alert women to this additional risk of smoking. A clinical trial of smoking cessation should be explored as a therapeutic intervention for primary HPV16 infection.",
author = "Wiley, {Dorothy J.} and Edward Wiesmeier and Emmanuel Masongsong and Gylys, {Karen H.} and Koutsky, {Laura A.} and Ferris, {Daron Gale} and Eliav Barr and Rao, {Jian Yu}",
year = "2006",
month = "5",
day = "1",
doi = "10.1158/1055-9965.EPI-05-0963",
language = "English (US)",
volume = "15",
pages = "915--920",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection

AU - Wiley, Dorothy J.

AU - Wiesmeier, Edward

AU - Masongsong, Emmanuel

AU - Gylys, Karen H.

AU - Koutsky, Laura A.

AU - Ferris, Daron Gale

AU - Barr, Eliav

AU - Rao, Jian Yu

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Objective: To determine the association between tobacco smoking and serologic evidence of human papillomavirus type 16 (HPV16)-specific antibodies among HPV16 DNA-positive women. Design, Setting, and Participants: Baseline health history, physical examination, and laboratory data for 205 HPV16 DNA-positive women with no prior cytologic evidence of squamous intraepithelial lesions who were enrolled subsequently in a randomized clinical trial. Main Outcome Measure: HPV16-L1 antibody (anti-HPV16 antibody) detected from serum using RIA or ELISA. Results: Eighty-seven percent (179 of 205) of women tested positive for HPV16 DNA using cervicovaginal swabs or lavage specimens, and 26 women showed similar results using swab specimens of external genitalia alone. HPV16-infected women who reported increasingly greater levels of daily cigarette smoking were less likely to test positive for anti-HPV16 antibodies than nonsmoking women (P = 0.02). Smokers were twice as likely as nonsmokers to test negative for anti-HPV16 antibodies, even after controlling for the effects of other covariates in the analyses (adjusted odds ratio, 0.5; 95% confidence limits, 0.2-0.9). Although Papanicolaou test findings and smoking characteristics were poorly correlated (r2 = 0.01), women who showed atypical cells of unknown significance or squamous intraepithelial lesion were twice as likely to test anti-HPV16 antibody positive as women who showed normal Papanicolaou tests (adjusted odds ratio, 2.0; 95% confidence limits, 1.1-3.7). Conclusion: These data suggest that smoking may influence the long-term risk for cancer by perturbing early immune responses to the virus and may increase the likelihood of persistent infection. Patient education messages should alert women to this additional risk of smoking. A clinical trial of smoking cessation should be explored as a therapeutic intervention for primary HPV16 infection.

AB - Objective: To determine the association between tobacco smoking and serologic evidence of human papillomavirus type 16 (HPV16)-specific antibodies among HPV16 DNA-positive women. Design, Setting, and Participants: Baseline health history, physical examination, and laboratory data for 205 HPV16 DNA-positive women with no prior cytologic evidence of squamous intraepithelial lesions who were enrolled subsequently in a randomized clinical trial. Main Outcome Measure: HPV16-L1 antibody (anti-HPV16 antibody) detected from serum using RIA or ELISA. Results: Eighty-seven percent (179 of 205) of women tested positive for HPV16 DNA using cervicovaginal swabs or lavage specimens, and 26 women showed similar results using swab specimens of external genitalia alone. HPV16-infected women who reported increasingly greater levels of daily cigarette smoking were less likely to test positive for anti-HPV16 antibodies than nonsmoking women (P = 0.02). Smokers were twice as likely as nonsmokers to test negative for anti-HPV16 antibodies, even after controlling for the effects of other covariates in the analyses (adjusted odds ratio, 0.5; 95% confidence limits, 0.2-0.9). Although Papanicolaou test findings and smoking characteristics were poorly correlated (r2 = 0.01), women who showed atypical cells of unknown significance or squamous intraepithelial lesion were twice as likely to test anti-HPV16 antibody positive as women who showed normal Papanicolaou tests (adjusted odds ratio, 2.0; 95% confidence limits, 1.1-3.7). Conclusion: These data suggest that smoking may influence the long-term risk for cancer by perturbing early immune responses to the virus and may increase the likelihood of persistent infection. Patient education messages should alert women to this additional risk of smoking. A clinical trial of smoking cessation should be explored as a therapeutic intervention for primary HPV16 infection.

UR - http://www.scopus.com/inward/record.url?scp=33744756691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744756691&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-05-0963

DO - 10.1158/1055-9965.EPI-05-0963

M3 - Article

C2 - 16702370

AN - SCOPUS:33744756691

VL - 15

SP - 915

EP - 920

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -